Imatinib is a medication classified as a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain forms of cancer. It is sold under the brand name Gleevec, among others. Imatinib works by targeting and inhibiting specific protein kinases within malignant cells, preventing them from growing and dividing.
Imatinib is specifically indicated for the treatment of chronic myelogenous leukemia (CML), a type of cancer that affects the white blood cells. It is also used for the treatment of gastrointestinal stromal tumors (GISTs), which are rare tumors that can occur in the stomach or other parts of the digestive system.
The use of imatinib has revolutionized the treatment of CML and GISTs, significantly improving patient outcomes and overall survival rates. It has been shown to effectively induce remission and minimize disease progression in many cases.
Despite its effectiveness, imatinib is not without potential side effects. Common adverse reactions include nausea, vomiting, diarrhea, muscle cramps, fluid retention, and fatigue. In rare cases, more serious side effects such as liver dysfunction, heart problems, and severe bleeding can occur.
Imatinib is typically administered orally in the form of a tablet or capsule. The dosage and duration of treatment may vary depending on the specific cancer being treated and the patient's individual response. Regular monitoring and follow-up with a healthcare professional are essential to ensure optimal treatment outcomes.
